Darolutamide Receives FDA Approval for Newly Diagnosed Metastatic Castration-Sensitive Prostate Cancer

On June 3, 2025, the US Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer) , an androgen receptor inhibitor, for newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) as single-agent treatment . This decision marks darolutamide's third FDA-approved clinical indication and offers an important alternative for patients and oncologists seeking effective systemic treatment without chemotherapy .

Previously, darolutamide was approved only for non-metastatic castration-resistant disease and metastatic hormone-sensitive prostate cancer in combination with chemotherapy (docetaxel) . With the new approval, darolutamide can now also be used early in mCSPC patients who are unsuitable for chemotherapy or prefer not to receive it .

Castration sensitivitymeans that prostate cancer cells still depend on androgen hormones, such as testosterone, to grow. Castration resistancemeans that prostate cancer cells continue to grow despite testosterone suppression.

What Is Darolutamide?

Darolutamide is a second-generation androgen receptor inhibitor (ARi)developed by Bayer. It suppresses prostate cancer cell growth by blocking the intracellular effects of androgens such as testosterone. Its limited penetration of the blood–brain barrier means that central nervous system side effects, such as seizures, are less common than with other ARi agents.

Previous FDA Approvals

With this latest approval, darolutamide can now also be used in metastatic disease without chemotherapy .

The ARANOTE Study: How Effective Is Darolutamide?

The new approval is based on ARANOTE , a randomized, double-blind, placebo-controlled Phase 3 study. Its details are as follows:

• A total of 669 patients with mCSPC were enrolled.
• All patients received a concurrent GnRH analogue or had previously undergone bilateral orchiectomy.
• Patients were randomly assigned to darolutamide or placebo.

🔍 Main Result: Radiographic Progression-Free Survival (rPFS)

• In the darolutamide arm, median radiographic progression-free survival (rPFS) was not reached.
• Median rPFS in the placebo arm: 25 months (95% CI: 19, NR)

📌 Compared with a GnRH analogue alone, darolutamide treatment produced a 46% reduction in the risk of disease progression . Hazard Ratio (HR): 0.54 (95% CI: 0.41–0.71), p < 0.0001

🧬 Overall Survival (OS)

• HR: 0.78 (95% CI: 0.58–1.05)
• Although statistical significance for overall survival has not yet been reached, the trend favors darolutamide.

Safety Profile: No Surprises, Within Expectations

Darolutamide's safety profile is consistent with previous studies:

The most common side effects:

• Fatigue
• Musculoskeletal pain
• Rash
• Blood pressure changes

Serious warnings:

• Risk of ischemic heart disease
• Risk of seizures

Dosage and Administration

• Recommended dose: 600 mg (two 300 mg tablets)
• How to take it: Twice a day, with food
• Duration of treatment: Until disease progression or the development of intolerable adverse effects

Clinical Commentary: A New Era in Prostate Cancer Management

With this third approval, darolutamide can now be used across different stages of prostate cancer and patient groups as follows:

1. In nmCRPC: Early treatment aimed at delaying the development of metastases
2. In high-volume mCSPC: In combination with docetaxel
3. In the general mCSPC population: As a single agent, particularly in patients unsuitable for chemotherapy

Conclusion: An Antiandrogen with an Expanding Role

Darolutamide has become notable not only for its biological activity but also for patient tolerability and flexibility of use . As of 2025, it has established itself as an option in chemotherapy-free mCSPC treatment that is effective and safe.

Manage preferences to view external content